Colin Hislop, MD

Juvena Therapeutics
Redwood city, California, United States

Disclosure information not submitted.

Presentation(s):

• SAT-050 - JUV-161 Preserves Muscle Mass and Function during Disuse-Induced Atrophy in Mice

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-052 - PK and Safety of JUV-161 - an Insulin-Like Growth Factor 2 Fusion Protein Therapeutic in Healthy Human Volunteers

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SUN-040 - JUV-161 as A Disease-Modifying Therapeutic for Myotonic Dystrophy Type 1

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• SUN-045 - Pharmacodynamic Serum Biomarker for JUV-161 - an Insulin-Like Growth Factor 2 Fusion Protein Therapeutic Treatment

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• SUN-641 - JUV-161 Improves Glucose Metabolism and Muscle Health as Monotherapy and in Combination in Type 2 Diabetic Mice

  Sunday, June 14, 2026
  9:00 AM - 4:00 PM CT

• MON-706 - A Secreted Protein Therapeutic, JUV-161, Improves Muscle Structure and Function in Age-Related Sarcopenia

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT